Pre-exposure (PrEP)
Pre-exposure Prophylaxis (PrEP)
IAS 2013: Bangkok Tenofovir Study and iPrEx Find PrEP Efficacy Is Related to Drug Exposure
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 16 July 2013 00:00
- Written by Gus Cairns
A pair of late-breaker presentations at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur provided new data about 2 studies of pre-exposure prophylaxis (PrEP) for injecting drug users and men who have sex with men and transgender women.
IAS 2013: PrEP Shown Effective for Injection Drug Users [VIDEO]
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Tuesday, 16 July 2013 00:00
- Written by Gregory Fowler
Researchers at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur provided further details from the Bangkok Tenofovir Study, which showed that tenofovir pre-exposure prophylaxis, or PrEP, reduced the risk of HIV infection among people who inject drugs.
CROI 2013: Women's PrEP Trial Does Not Show HIV Risk Reduction [VIDEO]
- Details
- Category: HIV Prevention
- Published on Sunday, 24 March 2013 00:00
- Written by Gregory Fowler
Long-awaited results from the VOICE trial of post-exposure prophylaxis (PrEP) for women in Africa, presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta, was not able to show that daily oral tenofovir plus emtricitabine (the drugs in Truvada) could lower the risk of HIV acquisition.
IAS 2013: iPrEx Participants Interested in Continuing HIV Pre-exposure Prophylaxis [VIDEO]
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 03 July 2013 00:00
- Written by Gregory Fowler
A majority of participants in an extension of the iPrEx pre-exposure prophylaxis (PrEP) trial said they would like ongoing open-label access to Truvada for HIV prevention, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
CROI 2013: Maraviroc Does Not Prevent Immune Reconstitution Syndrome [VIDEO]
- Details
- Category: HIV Prevention
- Published on Sunday, 24 March 2013 00:00
- Written by Gregory Fowler
The CCR5 co-receptor blocker maraviroc (Selzentry) did not reduce the risk of developing immune reconstitution inflammatory syndrome (IRIS) after starting antiretroviral therapy (ART), according to study findings presented at the recent 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
Web Design and Development by